CYTODYN INC (CYDY:OTCMKTS)
$0.2392 -0.0208 (-8%)
Analysed CYTODYN INC (CYDY:OTCMKTS) News Sources
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
21-04-2026
yahoo.com
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
27-04-2026
yahoo.com
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
04-06-2026
yahoo.com
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
11-06-2026
yahoo.com
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
01-09-2026
yahoo.com
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
19-09-2026
marketbeat.com
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
08-10-2026
yahoo.com
CytoDyn to Host Investor Webcast
15-10-2026
yahoo.com
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
19-10-2026
yahoo.com
CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO
19-10-2026
marketbeat.com
What is the current price of CYTODYN INC (CYDY:OTCMKTS)?
The current price of CYTODYN INC (CYDY:OTCMKTS) is $0.2392.
CYTODYN INC (CYDY:OTCMKTS) absolute price change since previous trading day?
The absolute price change of CYTODYN INC (CYDY:OTCMKTS) since the previous trading day is $-0.0208.
CYTODYN INC (CYDY:OTCMKTS) percentage price change since previous trading day?
The percentage price change of CYTODYN INC (CYDY:OTCMKTS) since the previous trading day is -8%.
What is the most recent average sentiment score for CYTODYN INC (CYDY:OTCMKTS)?
The most recent average sentiment score for CYTODYN INC (CYDY:OTCMKTS) is 81 out of 100.
What is the most recent average sentiment for CYTODYN INC (CYDY:OTCMKTS)?
The most recent sentiment for CYTODYN INC (CYDY:OTCMKTS) is .
SEC-8K** Filing Available For CYTODYN INC (CYDY:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.